Zentalis Pharmaceuticals, Inc. (ZNTL) Ownership
ZNTL ownership summary
as of October 18, 2026- Institutions
- 50.8% of shares outstanding
- Insiders
- 21.85% of shares outstanding
- Shares outstanding
- 98.1M
- Float
- 56.6M shares available to trade
- Short interest
- 7.11% 6.0M shares short
- Days to cover
- 5.11 short interest up 24.5% vs prior month
- Institutions 50.79%
- Insiders 21.85%
- Other investors 27.36%
ZNTL top institutional holders
20 largest| # | Holder | % of shares | Shares | Value | Change | Reported |
|---|---|---|---|---|---|---|
| 1 | 5AM Venture Management, LLC | 4.02% | 3.9M | $8.4M | — | June 30, 2026 |
| 2 | BlackRock Inc | 3.83% | 3.8M | $8.0M | +2.5M (+195.6%) | June 30, 2026 |
| 3 | Squadron Capital Management LLC | 3.77% | 3.7M | $7.9M | −331,000 (−8.2%) | June 30, 2026 |
| 4 | Two Sigma Investments LLC | 3.08% | 3.0M | $6.4M | +68,410 (+2.3%) | June 30, 2026 |
| 5 | Vanguard Capital Management, LLC | 2.89% | 2.8M | $6.0M | +524,962 (+22.7%) | June 30, 2026 |
| 6 | Acadian Asset Management LLC | 2.73% | 2.7M | $5.7M | −166,352 (−5.8%) | June 30, 2026 |
| 7 | Citadel Advisors Llc | 2.34% | 2.3M | $4.9M | +566,320 (+32.7%) | June 30, 2026 |
| 8 | Renaissance Technologies Corp | 1.64% | 1.6M | $3.4M | −329,067 (−17.0%) | June 30, 2026 |
| 9 | Opaleye Management Inc | 1.44% | 1.4M | $3.0M | — | June 30, 2026 |
| 10 | Orbimed Advisors LLC | 1.42% | 1.4M | $3.0M | +1.4M (0.0%) | June 30, 2026 |
| 11 | Decheng Capital LLC | 1.35% | 1.3M | $2.8M | — | June 30, 2026 |
| 12 | Geode Capital Management, LLC | 1.31% | 1.3M | $2.7M | +663,081 (+106.8%) | June 30, 2026 |
| 13 | Bank of America Corp | 1.14% | 1.1M | $2.4M | −17,644 (−1.6%) | June 30, 2026 |
| 14 | Ishara Investments LP | 1.04% | 1.0M | $2.2M | −205,000 (−16.7%) | June 30, 2026 |
| 15 | PRIMECAP Management Company | 0.98% | 957K | $2.0M | — | June 30, 2026 |
| 16 | Pfizer Inc | 0.97% | 954K | $2.0M | — | June 30, 2026 |
| 17 | Soleus Capital Management, L.P. | 0.97% | 950K | $2.0M | +950,000 (0.0%) | June 30, 2026 |
| 18 | State Street Corp | 0.90% | 887K | $1.9M | +637,726 (+255.4%) | June 30, 2026 |
| 19 | Vanguard Portfolio Management, LLC | 0.82% | 809K | $1.7M | +447,948 (+124.2%) | June 30, 2026 |
| 20 | Connor Clark & Lunn Inv Mgmt Ltd | 0.77% | 758K | $1.6M | −33,968 (−4.3%) | June 30, 2026 |
Value at the latest close. Change = shares bought or sold in the latest quarterly filing (13F). In the top 20, 9 holders added 7.7M shares and 6 cut 1.1M.
ZNTL top mutual fund and ETF holders
20 largest| # | Holder | % of shares | Shares | Value | Change | Reported |
|---|---|---|---|---|---|---|
| 1 | Vanguard MStar Total Stk Mkt Idx Invest | 2.91% | 2.9M | $6.1M | +669,700 (+30.6%) | August 31, 2026 |
| 2 | iShares Russell 2000 ETF | 1.34% | 1.3M | $2.8M | −15,104 (−1.1%) | September 30, 2026 |
| 3 | PRIMECAP Odyssey Aggressive Growth | 0.69% | 676K | $1.4M | — | June 30, 2026 |
| 4 | Fidelity Enhanced Small Cap Core ETF | 0.61% | 595K | $1.3M | +1,248 (+0.2%) | September 30, 2026 |
| 5 | Fidelity Small Cap Index | 0.56% | 546K | $1.2M | +3,116 (+0.6%) | July 31, 2026 |
| 6 | iShares Russell 2000 Value ETF | 0.50% | 488K | $1.0M | +740 (+0.2%) | September 30, 2026 |
| 7 | Biotech Growth Ord | 0.48% | 470K | $1.0M | +244,568 (+108.3%) | June 30, 2026 |
| 8 | Vanguard Strategic Small-Cap Equity Inv | 0.33% | 320K | $682,580 | +111,130 (+53.1%) | June 30, 2026 |
| 9 | Vanguard Russell 2000 ETF | 0.30% | 290K | $616,703 | +1,007 (+0.3%) | September 30, 2026 |
| 10 | Vanguard US Opportunities Ins USD Acc | 0.27% | 262K | $557,890 | — | June 30, 2026 |
| 11 | Fidelity Extended Market Index | 0.25% | 245K | $521,464 | +1,166 (+0.5%) | August 31, 2026 |
| 12 | Vanguard Health Care ETF | 0.23% | 224K | $476,511 | +243 (+0.1%) | September 30, 2026 |
| 13 | Federated Hermes MDT Small Cap Core ETF | 0.22% | 211K | $450,476 | −1,764 (−0.8%) | September 30, 2026 |
| 14 | Dimensional US Small Cap ETF | 0.18% | 181K | $386,316 | — | September 30, 2026 |
| 15 | iShares Micro-Cap ETF | 0.16% | 158K | $335,961 | −1,088 (−0.7%) | September 30, 2026 |
| 16 | Avantis US Small Cap Equity ETF | 0.15% | 144K | $306,347 | +894 (+0.6%) | September 30, 2026 |
| 17 | Sun Life Global Mid Cap Fund I | 0.14% | 136K | $290,394 | — | July 31, 2026 |
| 18 | Schwab Small Cap Index | 0.12% | 122K | $259,198 | — | August 31, 2026 |
| 19 | Invesco RAFI US 1500 Small-Mid ETF | 0.12% | 114K | $242,481 | — | September 30, 2026 |
| 20 | DFA US Micro Cap I | 0.11% | 104K | $220,806 | +26,924 (+35.1%) | August 31, 2026 |
Funds report holdings monthly or quarterly; dates differ by fund.
ZNTL insider transactions
latest 10| Date | Name | Transaction | Price | Shares | Value |
|---|---|---|---|---|---|
| 2026-02-10 | Vincent Vultaggio | Sell | $2.42 | 6,894 | $16,683 |
| 2026-02-09 | Ingmar Bruns | Sell | $2.39 | 335 | $801 |
| 2026-02-09 | Vincent Vultaggio | Sell | $2.39 | 3,379 | $8,076 |
| 2026-02-06 | Ingmar Bruns | Sell | $2.43 | 2,962 | $7,198 |
| 2026-02-06 | Vincent Vultaggio | Sell | $2.43 | 29,951 | $72,781 |
| 2026-02-03 | Vincent Vultaggio | Sell | $2.52 | 556 | $1,401 |
| 2026-02-02 | Vincent Vultaggio | Sell | $2.55 | 2,540 | $6,477 |
| 2025-12-31 | Group Walters | Buy | $1.20 | 6,459,973 | $7.8M |
| 2025-12-15 | Matrix Capital Management Comp | Sell | $1.33 | 7,500,000 | $10.0M |
| 2025-04-30 | Scott Dunseth Myers | Buy | $1.40 | 21,000 | $29,400 |
Reported trades by company officers, directors and other filers (including disclosures by members of Congress where EODHD lists them). "—" where the filing gives no share count.
ZNTL shares outstanding
Year-end shares outstanding, adjusted for splits.
Who owns ZNTL
Institutional investors own 50.8% of Zentalis Pharmaceuticals's shares and insiders 21.85%. The largest holder is 5AM Venture Management, LLC with 4.02% of the shares (3.9M), as of June 30, 2026. Among the top 20 institutions, 9 added shares and 6 reduced their stake in the latest filings. Short interest is 7.11% of the float, or 5.11 days of average trading volume. The share count rose 107.7% since 2019.
Related: ZNTL analyst forecast, ZNTL key metrics. See the ZNTL stock overview for the latest quote and news.
ZNTL ownership FAQ
Who owns the most Zentalis Pharmaceuticals stock?
The largest shareholders of Zentalis Pharmaceuticals are 5AM Venture Management, LLC (4.02%), BlackRock Inc (3.83%), Squadron Capital Management LLC (3.77%), Two Sigma Investments LLC (3.08%), Vanguard Capital Management, LLC (2.89%).
What percentage of Zentalis Pharmaceuticals is owned by institutions?
Institutions hold 50.8% of Zentalis Pharmaceuticals's shares outstanding; insiders hold 21.85%.
Which funds own Zentalis Pharmaceuticals?
The largest fund holders of Zentalis Pharmaceuticals are Vanguard MStar Total Stk Mkt Idx Invest (2.91%), iShares Russell 2000 ETF (1.34%), PRIMECAP Odyssey Aggressive Growth (0.69%), Fidelity Enhanced Small Cap Core ETF (0.61%), Fidelity Small Cap Index (0.56%).
What is Zentalis Pharmaceuticals's short interest?
6.0M shares of Zentalis Pharmaceuticals were sold short, 7.11% of the float; at the average daily volume it would take 5.11 days to cover.
Are insiders buying or selling Zentalis Pharmaceuticals?
Of the latest 10 reported insider transactions in Zentalis Pharmaceuticals (since April 30, 2025), 2 were purchases and 8 were sales.
How many shares of Zentalis Pharmaceuticals are outstanding?
Zentalis Pharmaceuticals has 98.1M shares outstanding, of which 56.6M are in the public float.